Shannon Harris

Shannon Harris has a diverse and extensive work experience in the field of clinical assays and vaccine research and development. They began their career as a Post-doctoral Fellow at Albert Einstein College of Medicine and later worked as a Research Associate at Children's Hospital Oakland Research Institute.

In 2004, Shannon joined Pfizer, where they held various roles over the years. As a Principle Research Scientist, they focused on antibody-antigen interactions with bacterial polysaccharides. They also worked on and managed the development and validation of biofunctional assays for bacterial vaccines, including the serum bactericidal assay (SBA) for meningococcal assays.

During their time at Pfizer, Shannon progressed to roles such as Senior Principal Scientist, Senior Manager, and Director. As a Director, they led the Biofunctional Assays and Cell Culture teams within the High Throughput Clinical Testing (HTCT) Group of Vaccine Research and Development, supporting Pfizer's vaccine portfolio from proof of concept to licensure and post-marketing commitments.

In 2019, Shannon joined Seqirus as the Head of Clinical Serology, where they showed their expertise in this area until 2021. Currently, Shannon holds the position of Vice President and Head of Clinical Assays at HilleVax, starting in 2022.

Overall, Shannon Harris has a strong background in clinical assays and vaccine research and has made significant contributions throughout their career.

Shannon Harris pursued their higher education from 1986 to 1997 at Simon Fraser University. During this period, they earned both a Bachelor of Science (BSc) and a Doctor of Philosophy (PhD) degree in Chemistry.